Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Inclusion Criteria:

- BMI above or equal to 25 and below or equal to 40 kg/m^2

- Subjects diagnosed with T2D (Type 2 diabetes) treated with diet and exercise and/or
who have been on a stable dose of metformin for at least 30 days prior to screening

- HbA1c 7.0-9.5% (53-80 mmol/mol) (both inclusive)

Exclusion Criteria:

- Subjects on selected oral medication with a narrow therapeutic window, such as
warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline, theophylline and
anticonvulsants

- History of chronic pancreatitis or idiopathic acute pancreatitis

- Chronic malabsorption, regardless of aetiology

- History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease

- Treatment with glucose lowering agent(s) other than metformin as stated in the
inclusion criteria in a period of 90 days before the screening visit